These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 14718791)

  • 1. Inhibition of HER1 signaling pathway enhances antitumor effect of endocrine therapy in breast cancer.
    Kurebayashi J; Okubo S; Yamamoto Y; Sonoo H
    Breast Cancer; 2004; 11(1):38-41. PubMed ID: 14718791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells.
    Okubo S; Kurebayashi J; Otsuki T; Yamamoto Y; Tanaka K; Sonoo H
    Br J Cancer; 2004 Jan; 90(1):236-44. PubMed ID: 14710235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance.
    Johnston SR; Martin LA; Head J; Smith I; Dowsett M
    J Steroid Biochem Mol Biol; 2005 May; 95(1-5):173-81. PubMed ID: 15996863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro.
    Gee JM; Harper ME; Hutcheson IR; Madden TA; Barrow D; Knowlden JM; McClelland RA; Jordan N; Wakeling AE; Nicholson RI
    Endocrinology; 2003 Nov; 144(11):5105-17. PubMed ID: 12960029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistance.
    Dowsett M; Nicholson RI; Pietras RJ
    Breast Cancer Res Treat; 2005; 93 Suppl 1():S11-8. PubMed ID: 16247595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancer.
    Garon EB; Pietras RJ; Finn RS; Kamranpour N; Pitts S; Márquez-Garbán DC; Desai AJ; Dering J; Hosmer W; von Euw EM; Dubinett SM; Slamon DJ
    J Thorac Oncol; 2013 Mar; 8(3):270-8. PubMed ID: 23399957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer.
    Siegfried JM; Gubish CT; Rothstein ME; Henry C; Stabile LP
    J Thorac Oncol; 2012 Mar; 7(3):485-95. PubMed ID: 22258476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
    Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
    BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer.
    Nicholson RI; Hutcheson IR; Harper ME; Knowlden JM; Barrow D; McClelland RA; Jones HE; Wakeling AE; Gee JM
    Ann N Y Acad Sci; 2002 Jun; 963():104-15. PubMed ID: 12095935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of the estrogen-signaling pathway by p21(WAF1/CIP1) in estrogen receptor-negative breast cancer cells.
    Chen X; Danes C; Lowe M; Herliczek TW; Keyomarsi K
    J Natl Cancer Inst; 2000 Sep; 92(17):1403-13. PubMed ID: 10974076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
    Ferrer-Soler L; Vazquez-Martin A; Brunet J; Menendez JA; De Llorens R; Colomer R
    Int J Mol Med; 2007 Jul; 20(1):3-10. PubMed ID: 17549382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cooperative effect of gefitinib and fumitremorgin c on cell growth and chemosensitivity in estrogen receptor alpha negative fulvestrant-resistant MCF-7 cells.
    Liu H; Cheng D; Weichel AK; Osipo C; Wing LK; Chen B; Louis TE; Jordan VC
    Int J Oncol; 2006 Nov; 29(5):1237-46. PubMed ID: 17016657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combine therapy of gefitinib and fulvestrant enhances antitumor effects on NSCLC cell lines with acquired resistance to gefitinib.
    Xu R; Shen H; Guo R; Sun J; Gao W; Shu Y
    Biomed Pharmacother; 2012 Jul; 66(5):384-9. PubMed ID: 22560634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors.
    Lu C; Speers C; Zhang Y; Xu X; Hill J; Steinbis E; Celestino J; Shen Q; Kim H; Hilsenbeck S; Mohsin SK; Wakeling A; Osborne CK; Brown PH
    J Natl Cancer Inst; 2003 Dec; 95(24):1825-33. PubMed ID: 14679152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ErbB3 downregulation enhances luminal breast tumor response to antiestrogens.
    Morrison MM; Hutchinson K; Williams MM; Stanford JC; Balko JM; Young C; Kuba MG; Sánchez V; Williams AJ; Hicks DJ; Arteaga CL; Prat A; Perou CM; Earp HS; Massarweh S; Cook RS
    J Clin Invest; 2013 Oct; 123(10):4329-43. PubMed ID: 23999432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fulvestrant increases gefitinib sensitivity in non-small cell lung cancer cells by upregulating let-7c expression.
    Shen H; Liu J; Wang R; Qian X; Xu R; Xu T; Li Q; Wang L; Shi Z; Zheng J; Chen Q; Shu Y
    Biomed Pharmacother; 2014 Apr; 68(3):307-13. PubMed ID: 24268810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
    McKeage K; Curran MP; Plosker GL
    Drugs; 2004; 64(6):633-48. PubMed ID: 15018596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
    Ghayad SE; Vendrell JA; Ben Larbi S; Dumontet C; Bieche I; Cohen PA
    Int J Cancer; 2010 Jan; 126(2):545-62. PubMed ID: 19609946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects.
    Stabile LP; Lyker JS; Gubish CT; Zhang W; Grandis JR; Siegfried JM
    Cancer Res; 2005 Feb; 65(4):1459-70. PubMed ID: 15735034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice.
    O'Regan RM; Osipo C; Ariazi E; Lee ES; Meeke K; Morris C; Bertucci A; Sarker MA; Grigg R; Jordan VC
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2255-63. PubMed ID: 16609042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.